Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
about
HIV and the chemokine system: 10 years later.Clinical significance of HIV-1 coreceptor usage.Access denied? The status of co-receptor inhibition to counter HIV entryAccelerated immunodeficiency by anti-CCR5 treatment in HIV infectionX4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process.A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression.Reappearance of an 11-year-old sequence in an HIV-1 infected patient during treatment interruption.Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.Genomic analysis of HIV type 1 strains derived from a mother and child pair of long-term nonprogressorsNaïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.Co-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individualsChemokine receptors: emerging opportunities for new anti-HIV therapies.Persistence and emergence of X4 virus in HIV infection.Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapyTreatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progressionEvolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.A novel denaturing heteroduplex tracking assay for genotypic prediction of HIV-1 tropism.Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic.HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation.Natural Scrub Typhus Antibody Suppresses HIV CXCR4(X4) VirusesA genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral Therapy: a Bayesian approach.Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.Correlating HIV tropism with immunological response under combination antiretroviral therapy.HIV-1 coreceptor switch during 2 years of structured treatment interruptions.High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatmentEmergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.Fusion/entry inhibitors as therapies for HIV.
P2860
Q27473020-EBC7AD92-AF11-4B2E-96C7-A3C1630DB107Q27691426-6D6C86B3-2851-4A44-AA8D-72DA05928773Q28300187-5FE61B1F-7D10-4574-B78A-1173FB1D3C95Q28475890-A1886751-5238-4FAD-AD89-42CCE0AF6EB3Q31117473-39241931-49FF-4DDC-AB7D-8AE693B28E48Q31143676-27B6B452-BB4D-462F-BA66-9DD063D7D381Q33302143-D956E2F2-6E19-4267-BE13-A58026AFD10BQ33788810-6875BA8E-50DA-44AE-B3B3-53F5BA081428Q33886716-05EBF58D-54BD-46CF-81B2-56F117C38A04Q34079006-8B6597FB-CE5D-4A21-A52A-D8F22D6FFF4DQ34301735-8E2F9E5A-F921-4B25-AB78-15E9702470FFQ34332104-1BCA8D98-6D32-4826-A5BE-D3AA90D5BF55Q34359107-446C6D89-AE28-4C52-AA1E-A45D2F9CA5FFQ35050395-54A2D3F7-C6B5-47EA-8D2D-8AE2D4A0E5EFQ35055322-8E0204FB-BEFE-4145-9DD6-DB4600266BBFQ35264750-EA65F433-5211-460D-9764-0BB1F35D6F75Q35547693-4C161FA5-74C0-428E-A32A-D402CDC4B845Q35849745-CAA8BE7A-B18A-4105-B71C-31FEFCDC4A40Q35953203-03CA2B21-C0D3-4CAE-8921-352C4044472EQ36157741-08BC7760-AFC2-4827-A2B3-86EA053F3F5DQ36480496-3C1DAC56-6BE3-4C1E-892C-2E1C13465583Q36690021-49A689C9-3732-4093-839D-7B3D172F51C1Q37481955-C69CE745-C0DF-4FF8-B3DF-F28D69D6B92CQ37517645-E79A0FC6-2C2E-4ED8-874A-0EBFC76A67C1Q37567887-8962721D-0F85-48E8-B627-0AD8C35F7583Q38887171-25CBB986-B18C-491D-9292-CE21B7941288Q38887176-62E5EBFF-B43F-45B9-B301-C3C646ACC8A4Q38894109-AC35AF2E-AAAB-43F2-BD08-5F0FDC2D2D27Q39109516-3F73B9B5-02D0-4077-9AC0-9ACC616D6DA5Q39588193-9E665557-0F4C-4920-B662-28CC7517C565Q40344458-7C68105B-985A-4A13-8F98-9B4F3CBCA815Q42928634-156FEEF8-DA26-43A0-BB22-EB790ADB2761Q45367160-9768DB31-18EE-4E9A-B832-07B29682F92DQ51736944-5131C271-5337-4A53-84ED-4DB151B9A76EQ53853233-5CEA55B2-7346-41A9-877A-055C0B65F84A
P2860
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
@ast
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
@en
type
label
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
@ast
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
@en
prefLabel
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
@ast
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
@en
P2093
P2860
P356
P1476
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
@en
P2093
C M Kitchen
S Philpott
U Mathur-Wagh
P2860
P304
P356
10.1172/JCI11526
P407
P577
2001-02-01T00:00:00Z